IMMUNEONCO-B(01541): The Phase II clinical trial of IMM2510 for pleuropulmonary soft tissue sarcoma has completed the first subject's enrollment and medication.

IMMUNEONCO-B(01541) announced that the phase II clinical trial of IMM2510 for recurrent and refractory alveolar soft part sarcoma (ASPS) has successfully completed the first subject's dosing. IMM2510, independently developed by the corporation, is a dual-specificity molecule targeting vascular endothelial growth factor (VEGF) and programmed cell death ligand-1 (PD-L1), utilizing a monoclonal antibody-receptor recombinant protein (mAbTrap) structure. IMM2510 can inhibit angiogenesis, shrink tumors, and increase tumor cell sensitivity to immune responses. It also activates T cells, natural killer cells, and macrophages through blocking the interaction of PD-L1/programmed cell death protein 1 (PD-1) and inducing Fc-mediated antibody-dependent cellular cytotoxicity (ADCC)/antibody-dependent cellular phagocytosis (ADCP) activities. Preliminary data from the phase I clinical trial of IMM2510 demonstrated good safety and positive efficacy. In evaluable patients, partial improvement was observed in each of the three different dose groups of IMM2510 (3mg/kg, 10mg/kg, and 20mg/kg). On September 11, 2023, IMM2510 completed the enrollment of phase I dose escalation patients, and the recommended dose for phase II was determined to be 20mg/kg, administered every two weeks (Q2W). Preclinical efficacy studies have shown that IMM2510 exhibits stronger synergistic anti-tumor activity compared to the combination of VEGF-blocking antibodies and PD-L1 antibodies. Preliminary data from the phase I dose escalation study of IMM2510 demonstrated positive efficacy in recurrent and refractory lung adenocarcinoma, lung squamous cell carcinoma, and thymoma.